** Absci Corp's ABSI.O shares down 2% at $4.82 premarket
after follow-on offering priced
** Artificial intelligence (AI) biologics firm late Tues
announced 16.7 mln shares at $4.50 for $75 mln raise with Morgan
Stanley and TD Cowen as joint bookrunners
** Offering price represents 8.5% discount to stock's last
sale
** Absci said plans to use net proceeds to fund development
of its internal asset programs, invest in its Integrated Drug
Creation platform, including related AI and wet-lab technologies
** Co has 92,9 mln shares outstanding for $457 mln market
value, and 68.1 mln shares of public float, according to LSEG
data
** ABSI has been on a tear recently, having more than
tripled over the past three months. In early Dec, co inked a
cancer-fighting antibody deal with UK-based drugmaker
AstraZeneca AZN.L
(Lance Tupper is a Reuters market analyst. The views expressed
are his own)
((lance.tupper@thomsonreuters.com
lance.tupper@tr.com 1-646-279-6380))